SHANGHAI, Nov. 6, 2012 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX) today announced shareholder resolutions adopted at its annual general meeting of shareholders held in Hong Kong on November 6, 2012.
At the meeting, WuXi PharmaTech shareholders approved the re-election of incumbent Class B directors Xuesong (Jeff) Leng, Zhaohui Zhang, and Ning Zhao, each to serve a three-year term.
About WuXi PharmaTech
WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech’s services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec.
For more information, please contact: | |
WuXi PharmaTech (Cayman) Inc. | |
Ronald Aldridge (for investors) | |
Director of Investor Relations | |
Tel: +1-201-585-2048 | |
Email: ir@wuxiapptec.com | |
Aaron Shi (for the media) | |
WuXi PharmaTech (Cayman) Inc. | |
Tel: +86-21-5046-4362 | |
Email: pr@wuxiapptec.com |
SOURCE WuXi PharmaTech (Cayman) Inc.
